Back to today’s briefing

Story perspectives

Eli Lilly's Orforglipron Shows Promise for Weight Loss

12/19/2025

44 4 Full Breakdown

Summary

Story summary

Eli Lilly and Company announced orforglipron maintained weight loss in a Phase 3 trial after switching from Wegovy and Zepbound.
Patients switching from Wegovy regained about 2 pounds.
Patients switching from Zepbound regained around 11 pounds.
The company has filed for FDA approval, which could expedite the review.
Eli Lilly and Novo Nordisk have set a maximum price of $149 per month.

1 of 1

Story summary

Eli Lilly and Company announced orforglipron maintained weight loss in a Phase 3 trial after switching from Wegovy and Zepbound.
Patients switching from Wegovy regained about 2 pounds.
Patients switching from Zepbound regained around 11 pounds.
The company has filed for FDA approval, which could expedite the review.
Eli Lilly and Novo Nordisk have set a maximum price of $149 per month.